The last article from the cycle elaborates on the applicability of the principles and approaches described in the guidance in special cases.
Table of content
The Central Drugs Standard Control Organization (CDSCO), an Indian regulating authority in the sphere of healthcare products, has published a guidance document dedicated to Good Clinical Practices. The document provides an overview of the best principles and approaches, as well as additional clarifications and recommendations to be considered by the parties responsible for clinical trials involving healthcare products in order to ensure compliance with the applicable legal framework.
Special Concerns in Clinical Research
The authority acknowledges that clinical research involves various types of studies, each with its unique challenges and ethical concerns. The relevant section of the document outlines the special concerns related to specific types of clinical research, including vaccines, contraceptives, surgical procedures, diagnostic agents, herbal remedies, stem cells, gene therapy, nanoparticles, and food supplements.
Clinical Research of Vaccines
According to the document, vaccine research follows distinct phases that differ slightly from drug research due to the nature of vaccines:
- Phase I: Involves the first introduction of a vaccine to human subjects, focusing on safety and biological effects, such as immunogenicity. This phase uses low-risk participants to study dose and route of administration.
- Phase II: Examines the vaccine’s effectiveness in a limited number of volunteers. Prophylactic vaccines are typically tested on healthy individuals, while therapeutic vaccines target patients suffering from the relevant disease.
- Phase III: Large-scale studies involving thousands of participants are conducted to assess the vaccine’s safety and efficacy in preventing disease. These studies are often multicenter trials.
Vaccine studies should follow specific guidelines to ensure participant safety and adherence to regulatory frameworks:
- Researchers must familiarize themselves with approval processes from agencies such as CDSCO, DBT, and GEAC, especially for vaccines developed using recombinant DNA technology.
- Vaccines containing live microorganisms carry risks of infection, which participants must be informed about.
- In studies with control groups, participants in the control group or those receiving ineffective vaccines may risk contracting the disease.
- The safety of vaccines produced through recombinant DNA techniques is not entirely known, requiring adherence to Department of Biotechnology guidelines.
- Protocols should include criteria for participant selection, frequency of administration, and testing methods. Quality control data of the vaccine batch must also be provided to the investigator.
Clinical Research of Contraceptives
Clinical research on contraceptives follows standard procedures, but certain specific concerns must be addressed:
- Participants must be informed about alternative contraceptive options.
- If an implant is used, proper follow-up for its removal is required, even if the participant withdraws from the study.
- In the case of contraceptive failure, children born as a result must be followed for any abnormalities if the woman chooses not to terminate the pregnancy.
Clinical Research with Surgical Procedures and Medical Devices
The guidance additionally emphasizes that research involving surgical procedures or medical devices should prioritize the rights, safety, and well-being of participants over scientific or societal interests. Ethical principles originating from the Declaration of Helsinki must guide the study.
Clinical investigations require approval from the Central Licensing Authority, and studies must be conducted according to prescribed guidelines. Devices claiming equivalence to an existing device must receive approval from the authority.
The ethics committee oversees the conduct of clinical investigations and ensures participant safety. Sponsors and investigators are responsible for compensating participants for any injuries caused during the study.
Clinical Research with Diagnostic Agents (Radioactive Materials and X-Rays)
Clinical research involving radiation-based diagnostic agents must carefully balance risks and benefits.
The use of radioactive materials and X-rays should follow regulatory limits set by BARC, and also comply with the following requirements:
- Informed consent must be obtained before any diagnostic procedure involving radiation.
- Research should aim to gather necessary information while minimizing participant exposure to radiation.
- Safety measures should be in place to protect participants, especially women of childbearing age, to avoid risks to embryos.
- Non-radioactive diagnostic agents are treated as drugs and follow drug research guidelines.
Clinical Research of Herbal Remedies and Medicinal Plants
Herbal remedies used in clinical research should follow procedures similar to those applied in the evaluation of allopathic drugs, with some special considerations for traditional Indian systems of medicine (Ayurveda, Siddha, Unani). Clinical trials involving herbal remedies must include co-investigators from the respective traditional systems of medicine.
It is considered unethical for an allopathic physician to conduct these studies without proper knowledge of these systems. The study must follow good clinical practices (GCP), and informed consent is crucial.
Research involving traditional knowledge or folklore medicine must ensure that the tribe or community from which the knowledge is derived receives appropriate compensation if the medicine is commercialized.
Herbal products fall into three categories:
- Traditional Knowledge-Based: These are based on ancient texts or long-standing use in traditional systems of medicine.
- New Uses or Preparations: These require toxicological data as they may involve new uses or preparation methods not described in traditional texts.
- New Drugs: Herbal compounds not previously used or described must undergo regulatory procedures as a new drug.
Clinical Research of Stem Cells
Stem cell research presents unique scientific, ethical, and regulatory challenges. Stem cells, due to their regenerative potential, are categorized as investigational new drugs (IND) or investigational new entities (INE) when used for clinical applications.
Stem cells require processing before clinical use, which poses risks such as contamination, tumorigenicity, and immunological incompatibility. Research involving stem cells must receive approval from the Institutional Committee for Stem Cell Research (ICSCR) and adhere to guidelines set by regulatory bodies such as CDSCO, DBT, and GEAC.
Ethical considerations, such as compensation for injuries and protection from exploitation, must be addressed, particularly for underprivileged groups.
Gene Therapy and Nanoparticles in Clinical Research
Gene therapy involves using functioning genes to treat genetic diseases by replacing or regulating defective genes. It raises significant ethical concerns due to its potential impact on human cells and the risk of misuse (e.g., in germline modification or enhancement).
In India, germline gene therapy is banned. Researchers must carefully select gene delivery vectors and design studies to minimize off-target effects and immune reactions.
There are concerns regarding the potential for teratogenicity, immune activation, and unwanted mutations. These risks must be disclosed to participants.
Nanotechnology in pharmaceuticals offers the potential for targeted drug delivery, improving efficacy and safety. However, the altered properties of nanoparticles raise concerns regarding their pharmacokinetics, biodistribution, and toxicity.
Clinical trials for nanoparticles must be carefully designed to account for the unique behavior of the drug delivery system and its interaction with human tissues.
Clinical Research of Food Supplements
Food trials differ from drug trials in their design, objectives, and population. They tend to be more exploratory, focusing on specific claims about human health.
Best practices in this sphere would include:
- Food trials should be built around a clear claim related to human health and follow principles of good clinical practices.
- The trial design must ensure that the food being tested is safe, and participants must be adequately informed and provide informed consent.
- The outcomes and measures should be clearly defined, and the trial must evaluate both safety and efficacy.
Conclusion
In summary, special concerns in clinical research vary widely depending on the type of study being conducted. Vaccine research, contraceptive studies, surgical procedures, diagnostic agents, herbal remedies, stem cells, gene therapy, nanoparticles, and food supplements each present unique ethical, scientific, and regulatory challenges, so compliance with the established guidelines, as well as the relevant regulatory requirements, ensuring participant safety, and maintaining high standards of data integrity, are critical to the successful conduct of these studies.
How Can RegDesk Help?
RegDesk is an AI-powered Regulatory Information Management System that provides medical device companies with regulatory intelligence for over 120 markets worldwide. It can help you prepare and publish global applications, manage standards, run change assessments, and obtain real-time alerts on regulatory changes through a centralized platform. Global expansion has never been this simple.
